

DISCOUNT DISTRIBUTION ANALYSIS OF ORIGINAL MEDICINES

WHICH HAS NO GENERICS IN TURKEY

Esin Tuna¹, Fatma Betul Yenilmez¹, E. Kagan Atikeler¹, Guvenc Kockaya²

¹Hacettepe University, Social Sciences, Hacettepe Beytepe Campus, Ankara, Turkey, ²Health Economics and Policy Association, Ankara, Turkey

Objectives

Pharmaceutical industry continues to grow and drug prices are a burden for countries. Reference price system is assumed that such a practice concerning medicines will lead to a decrease in medicine expenditures as medicine prices decrease. The objectives of this analysis to determine the distribution of discount of original medicines which has no generics from the reimbursement agency perspective in Turkey.

Methodology

In the analysis, "Detailed Price List" data published on the website of the Ministry of Health's Turkish Medicines and Medical Devices Agency(TMMDA) and "Annex 4-A Funded Medicines List" data published by Social Security Institution (SSI) were used. The lists were merged using the Excel software and generic medicine including genericized original medicines with different pricing and payment conditions compared to original medicines with no generics and other specific medicines such as blood products, enteral nutrition products, etc. and specific conditions such as medicines with no reimbursement were excluded. The analysis was made with a total of 568 original medicines with no generic. Ex-factory prices were used in the analysis. The reference prices of all original medicines (100 %) are calculated by multiplying their actual reference price values with the periodic Euro value in the price list used in Turkey.

Results

A comparison between ex-factory prices in TL and actual reference prices in TL revealed that 42.6% of the medicines had the same price, while 57.4% had a different price. The distribution of discount rates applied by SSI for 370 original medicines with a 41% discount rate and 99 original medicines with a 32.5% discount rate were found.

Conclusion

In this analysis the mandatory discount rate for original drugs of 41% discount is mostly implemented by SSI. In rare cases, higher or lower discount rate can be applied. This is compatible with the implementation of the original drug reimbursement policy rules. However, further analysis should be done to obtaining more detailed information.

Chart 1. Discount Distributions Applied By SSI





Chart 2. Discount Distribution Rates



References

1. Arslanhan Memis S., (2013). Fiyat ve Geri Ödeme Politikalarının İlaç Sanayii Üzerine Etkisi, Türkiye Ekonomi Politikaları Araştırma Vakfı Politika Notu. (<http://www.tepav.org.tr/upload/files/1357211706-5>)
2. Atikeler, K., Özcelikay, G., (2014). Türkiye ve Bazı Ülkelerde İlaçta Fiyatlandırma ve Geri Ödeme Sistemlerinin Karşılaştırılması, Yüksek Lisans Tezi, Ankara Üniversitesi Sağlık Bilimleri Enstitüsü, Ankara.
3. Caliskan, Z., (2008). Sağlık Hizmetlerinde Önceliklerin Belirlenmesinde Ekonomik Değerlendirme Yöntemi Olarak Maliyet-Etklilik Analizi, Suleyman Demirel Üniversitesi, İktisadi ve İdari Bilimler Fakültesi Dergisi, (14)2: 311-332.
4. Caliskan, Z., (2009). Referans Fiyat ve İlaç Piyasası, Hacettepe Sağlık İdaresi Dergisi, (11)1: 50-51.
5. Dogan, E., (2014). Türkiye'de İlaçların Fiyatlandırılması Sunumu, Hacettepe Üniversitesi Eczacılık Fakültesi Ders Notu DPT (2006). Sekizinci Bes Yıllık Kalkınma Planı, İlaç Sanayii Özel İhtisas Komisyonu Raporu, Ankara.
6. Gulergun, E., Karakoc, H., Hatipoglu, C., (2013). Sektör Araştırması Raporu, Rekabet Kurumu. (<http://www.rekabet.gov.tr/File/?path=ROOT%2F1%2FDocuments%2FSekt%C3%B6rRaporu%2Filacrapor.pdf>, Access Date: 22.05.2015)